Gerald E. Quirk - 27 Mar 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal & Compliance Offic
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
27 Mar 2024
Transactions value $
-$39,387
Form type
4
Filing time
02 Apr 2024, 16:57:04 UTC
Previous filing
20 Oct 2023
Next filing
02 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +22,500 +92.58% 46,803 27 Mar 2024 Direct F1
transaction SYRS Common Stock Tax liability -$39,387 -7,046 -15.05% $5.59 39,757 28 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -22,500 -100% $0* 0 27 Mar 2024 Common Stock 22,500 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding on a restricted stock unit release.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on October 11, 2022. These restricted stock units vested as to one half (50%) of the shares on October 11, 2023, and vested as to one half (50%) of the shares on March 27, 2024.